BKM120 sensitizes BRCA-proficient triple negative breast cancer cells to olaparib through regulating FOXM1 and Exo1 expression

BRCA1 subcellular localization regulated by PI3K signaling pathway in triple-negative breast cancer MDA-MB-231 cells and hormone-sensitive T47D cells

(2020) Bin Ma et al.   Open Life Sciences

Targeting the PI3-kinase pathway in triple-negative breast cancer

(2019) J Pascual et al.   ANNALS OF ONCOLOGY

Ion Channels Involved in Substance P-Mediated Nociception and Antinociception

(2019) Chu-Ting Chang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Advances in Targeted Therapies for Triple-Negative Breast Cancer

(2019) Kelly E. McCann et al.   DRUGS

PARP inhibition — opportunities in pancreatic cancer

(2019) Shubham Pant et al.   Nature Reviews Clinical Oncology

Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks

(2019) Marie-Christine Caron et al.   Nature Communications

PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges

(2019) Mohammad A. Khan et al.   DRUG DISCOVERY TODAY

The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells

(2019) Gamze Guney Eskiler   JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

PI3K Inhibitors in Breast Cancer Therapy

(2019) Haley Ellis et al.   Current Oncology Reports

Emerging therapeutic modalities of PARP inhibitors in breast cancer

(2018) Xin Wang et al.   CANCER TREATMENT REVIEWS

Biomarkers for Homologous Recombination Deficiency in Cancer

(2018) Michal M Hoppe et al.   JNCI-Journal of the National Cancer Institute

Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP Inhibition

(2018) Pingping Fang et al.   MOLECULAR CANCER RESEARCH

Phosphorylation of PI3K regulatory subunit p85 contributes to resistance against PI3K inhibitors in radioresistant head and neck cancer

(2018) Myung Woul Han et al.   ORAL ONCOLOGY

PARP Inhibitors in Ovarian Cancer

(2018) Gloria Mittica et al.   Recent Patents on Anti-Cancer Drug Discovery

The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance

(2018) Shang Yao et al.   SEMINARS IN CANCER BIOLOGY

FoxM1-dependent RAD51 and BRCA2 signaling protects idiopathic pulmonary fibrosis fibroblasts from radiation-induced cell death

(2018) Jintaek Im et al.   Cell Death & Disease

Biomarkers for Homologous Recombination Deficiency in Cancer

(2018) Michal M Hoppe et al.   JNCI-Journal of the National Cancer Institute

Mechanisms of PARP inhibitor sensitivity and resistance

(2018) Alan D. D’Andrea   DNA REPAIR

PARP inhibitors: Clinical utility and possibilities of overcoming resistance

(2017) Benjamin G. Bitler et al.   GYNECOLOGIC ONCOLOGY

Mild hypothermia pretreatment protects against liver ischemia reperfusion injury via the PI3K/AKT/FOXO3a pathway

(2017) Qi Xiao et al.   Molecular Medicine Reports

The multifaceted roles of PARP1 in DNA repair and chromatin remodelling

(2017) Arnab Ray Chaudhuri et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

DNA damage repair in breast cancer and its therapeutic implications

(2017) Reem Ali et al.   PATHOLOGY

Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage

(2016) Andrea Sau et al.   Cell Stem Cell

Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance

(2016) Gabriela Nestal de Moraes et al.   CURRENT DRUG TARGETS

Targeting therapeutic liabilities engendered by PIK3R1 mutations for cancer treatment

(2016) Lydia WT Cheung et al.   PHARMACOGENOMICS

Poly(ADP-ribose)-binding promotes Exo1 damage recruitment and suppresses its nuclease activities

(2015) Abigael Cheruiyot et al.   DNA REPAIR

Persistent γH2AX: A promising molecular marker of DNA damage and aging

(2015) Mohammad Sabbir Siddiqui et al.   MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH

Dose-dependent effects of selenite (Se4+) on arsenite (As3+)-induced apoptosis and differentiation in acute promyelocytic leukemia cells

(2015) S Wang et al.   Cell Death & Disease

Tetraarsenictetrasulfide and Arsenic Trioxide Exert Synergistic Effects on Induction of Apoptosis and Differentiation in Acute Promyelocytic Leukemia Cells

(2015) Shuping Wang et al.   PLoS One

Poly(ADP-ribose) polymerases in double-strand break repair: Focus on PARP1, PARP2 and PARP3

(2014) Carole Beck et al.   EXPERIMENTAL CELL RESEARCH

Transcriptional Roles of PARP1 in Cancer

(2014) Matthew J. Schiewer et al.   MOLECULAR CANCER RESEARCH

Poly(ADP-Ribose) Polymerase 1 (PARP1) Overexpression in Human Breast Cancer Stem Cells and Resistance to Olaparib

(2014) Marine Gilabert et al.   PLoS One

FOXO3a Is a Major Target of Inactivation by PI3K/AKT Signaling in Aggressive Neuroblastoma

(2013) E. E. Santo et al.   CANCER RESEARCH

DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis

(2012) Wynand P. Roos et al.   CANCER LETTERS

BRCA1-directed, enhanced and aberrant homologous recombination

(2012) Seth M. Dever et al.   CELL CYCLE

Exo1 plays a major role in DNA end resection in humans and influences double-strand break repair and damage signaling decisions

(2012) Nozomi Tomimatsu et al.   DNA REPAIR

PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition

(2012) Yasir H. Ibrahim et al.   Cancer Discovery

Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer

(2012) Ashish Juvekar et al.   Cancer Discovery

AKT/FOXO Signaling Enforces Reversible Differentiation Blockade in Myeloid Leukemias

(2011) Stephen M. Sykes et al.   CELL

Resist or die: FOXO transcription factors determine the cellular response to chemotherapy

(2011) Ana R. Gomes et al.   CELL CYCLE